Follow the Money: Seres Therapeutics, Inc.


Follow the Money highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.

Seres Therapeutics, Inc. is a U.S. public pharmaceutical company that discovers and develops drugs to treat infectious, metabolic and inflammatory diseases. As reported in the July 2, 2015 issue of the PharmSource Lead Sheet, Seres raised $133 million in the completion of an initial public offering.

Corporate Highlights

  • Seres Therapeutics was incorporated in Delaware in 2010 under the name NewCo LS21. In October 2011, the company changed its name to Seres Health, Inc., and in May 2015, the company’s name was changed to Seres Therapeutics, Inc.
  • Corporate Headquarters: Cambridge, Massachusetts – approximately 7,461 square feet of office space.
  • Facility: Cambridge, Massachusetts – approximately 21,052 of laboratory and office space.
  • As of May 13, 2015, Seres had 44 full-time permanent employees, 33 of whom were engaged in research & development.

Sourcing Opportunities

  • Seres plans to use the proceeds to:
    • advance the clinical development of SER-109 for the treatment of C. difficile infection, in Phase II development.
    • advance the development of SER-262, SER-287 and SER-155 through pre-clinical development and file an investigational new drug application, for one or more of these product candidates.
    • fund current and future research & development activities and working capital and other general corporate purposes.
  • The company relies on third parties, such as contract research organizations, clinical data management organizations, medical institutions and clinical investigators, to conduct and manage all clinical trials.
  • Seres relies on third parties for the manufacture of product candidates for preclinical and clinical testing, as well as for commercial manufacture should any product candidate receive marketing approval.
  • The company has no sales, marketing or distribution infrastructure.


Product Candidate Indication Dosage Form Status Next Anticipated Step
Metabolic Diseases Type 2 diabetes and metabolic syndrome Unknown Discovery TBA
SER-301 Irritable bowel disease Oral Discovery TBA
SER-155 Drug resistant bacteria and post-Abx dysbiosis Oral Preclinical Preclinical screening expected to continue until identification of indication
SER-262 Primary C. difficile Oral Preclinical Initiation of clinical studies expected in middle of 2016
SER-287 Ulcerative colitis Oral Preclinical Initiation of Phase I trial by the end of 2015
SER-109 Recurrent C. difficile Capsule Phase II Results of Phase II trial expected in middle of 2016



(In $ thousands) 2014 2013
R&D Expenditures
General & Administrative Expenditures
Total Operating Expenses
Capital Expenditures

Contact Information

Seres Therapeutics, Inc. Key Officers
215 First Street Roger Pomerantz, MD, President & CEO
Cambridge, MA 02142, USA Michele (Shelley) Trucksis, MD, PhD, EVP & CMO
Phone: 617-945-9626 David Cook, PhD, CSO & EVP, R&D
Web: Matthew Henn, PhD, SVP & Head, Drug Discovery & Bioinformatics
John Aunins, PhD, CTO & EVP, Bioprocess & Manufacturing

Related posts:
Follow the Money: Fate Therapeutics, Inc.
Follow the Money: Viking Therapeutics, Inc.
Follow the Money: Intercept Pharmaceuticals, Inc.

Ryan is a Senior Research Analyst at PharmSource. He holds a BS degree in biology, with a minor in chemistry and a BA degree in Spanish, from the University of North Carolina at Chapel Hill. Prior to joining PharmSource, Ryan worked as a Research Technician in the Neuroscience Center of the UNC Chapel Hill School of Medicine, and has been a named author on research publications.

More posts by Ryan Worthen